^
Association details:
| Biomarker: | AKT1 E17K + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | rupitasertib (DIACC3010) (AKT inhibitor, p70S6K inhibitor, AKT1 inhibitor, AKT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
Published date:
10/18/2021
Excerpt:
...patient was a 48-year-old woman with ER +, PgR +, HER2-negative breast cancer....Pretreatment tumor molecular profiling demonstrated an AKT1 E17K mutation. She received 240 mg M2698 combined with tamoxifen and had a PR; her PFS duration was 2.7 months (liver metastases disappeared; lung, pancreatic and bone metastases: stable; new brain metastases).
Secondary therapy:
tamoxifen
DOI:
10.1186/s13045-021-01132-z
Trial ID:
